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Cachexia represents one of the primary complications of colorectal cancer due to
its effects on depletion of muscle and fat. Evidence suggests that chemotherapeutic
regimens, such as Folfiri, contribute to cachexia-related symptoms. The purpose of the
present study was to investigate the cachexia signature in different conditions associated
with severe muscle wasting, namely Colon-26 (C26) and Folfiri-associated cachexia.
Using a quantitative LC-MS/MS approach, we identified significant changes in 386
proteins in the quadriceps muscle of Folfiri-treated mice, and 269 proteins differentially
expressed in the C26 hosts (p< 0.05;−1.5≥ fold change≥+1.5). Comparative analysis
isolated 240 proteins that were modulated in common, with a large majority (218) that
were down-regulated in both experimental settings. Interestingly, metabolic (47.08%)
and structural (21.25%) proteins were the most represented. Pathway analysis revealed
mitochondrial dysfunctions in both experimental conditions, also consistent with reduced
expression of mediators of mitochondrial fusion (OPA-1, mitofusin-2), fission (DRP-1)
and biogenesis (Cytochrome C, PGC-1α). Alterations of oxidative phosphorylation
within the TCA cycle, fatty acid metabolism, and Ca2+ signaling were also detected.
Overall, the proteomic signature in the presence of both chemotherapy and cancer
suggests the activation of mechanisms associated with movement disorders, necrosis,
muscle cell death, muscle weakness and muscle damage. Conversely, this is consistent
with the inhibition of pathways that regulate nucleotide and fatty acid metabolism,
synthesis of ATP, muscle and heart function, as well as ROS scavenging. Interestingly,
strong up-regulation of pro-inflammatory acute-phase proteins and a more coordinated
modulation of mitochondrial and lipidic metabolisms were observed in the muscle of the
C26 hosts that were different from the Folfiri-treated animals. In conclusion, our results
suggest that both cancer and chemotherapy contribute to muscle loss by activating
common signaling pathways. These data support the undertaking of combination
strategies that aim to both counteract tumor growth and reduce chemotherapy side
effects.
Keywords: Folfiri, C26, proteomics, muscle, inflammation, cachexia, mitochondria, mitochondrial fusion and
fission
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INTRODUCTION
According to the American Cancer Society, colorectal cancer
represents the third leading cause of cancer-related deaths in the
United States (American Cancer Society, 2015). Each year, about
150,000 Americans are diagnosed with colorectal cancer, and
one third of those individuals die from the disease (Siegel et al.,
2015). Colorectal cancer therapy frequently includes treatment
with 5-fluorouracil (5-FU), Leucovorin (LV) and CPT-11, a
combination also known as Folfiri. Among the several side effects
frequently associated with the administration of Folfiri, increased
fatigue represents one of the most common (Montagnani et al.,
2011). Notably, cachexia poses a serious problem for patients’
quality of life and survival.
Cachexia is a devastating condition associated with several
types of malignant cancers and is comorbid in 22–55% of
all colorectal cancer cases (Thoresen et al., 2013). A major
contributor of colorectal cancer morbidity and mortality,
cachexia is primarily responsible for body and muscle weight loss
and correlates with tumor burden, increased pro-inflammatory
cytokine levels, fatigue, and reduced response to chemo- and
radio-therapy (Ravasco et al., 2007; Bapuji and Sawatzky, 2010;
Fearon et al., 2012). Studies suggest that cachexia may result
from tumor-host interactions or activation of an inflammatory
response. We reported that blocking muscle wasting can prolong
life even in the absence of effects on tumor growth (Benny Klimek
et al., 2010). Hence, targeting cachexia per se could improve
outcomes and enhance tumor-free survival.
Notably, although the molecular mechanisms responsible for
the development of cancer cachexia have been studied for quite
some time, it is not completely clear whether cancer treatments
also play a causative role in the development of cachexia. Along
this line, the use of cytotoxic and anti-proliferative drugs for
the treatment of cancer is frequently accompanied by several
pronounced side effects, including nausea, diarrhea, anorexia and
fatigue, all of which are responsible for significantly decreasing
the quality of life of cancer patients and increasing morbidity and
mortality. Interestingly, findings show that chemotherapy can
promote cachexia development regardless of its effects on tumor
growth (Damrauer et al., 2008; Garcia et al., 2008).
Furthermore, it has also been reported that cancer patients
affected with muscle depletion (regardless of body weight) are
more susceptible to developing severe drug-associated toxicity
and show a poorer prognosis. Conversely, subjects with higher
muscle mass or not showing sarcopenia are generally more
resistant andmay tolerate higher doses of chemotherapy (Antoun
et al., 2010; Prado et al., 2011; Thoresen et al., 2013; Jung et al.,
2015; Stene et al., 2015). We recently reported that Folfox and
Folfiri, which are chemotherapeutics utilized for the treatment
of solid tumors, may contribute to the development of cachexia
and muscle weakness by promoting oxidative stress-associated
MAPK activation and by affecting the muscle mitochondrial
Abbreviations: C26, Colon-26 adenocarcinoma; LC-MS/MS, liquid
chromatography tandem mass spectrometry; 5-FU, 5-fluorouracil; LV, leucovorin;
ROS, reactive oxygen species; TCA, tricarboxylic acid; ATP, adenosine
triphosphate; MAPK, mitogen-activated protein kinase; APR, acute phase
response.
pool (Barreto et al., 2016). Despite this, it is still partially
unknown whether chemotherapy directly promotes cachexia
and whether this occurs by activating the same molecular
mechanisms associated with muscle wasting in the presence of
a tumor.
The purpose of this study was to identify and compare
signaling pathways associated with cancer- and chemotherapy-
induced muscle wasting based on differences in protein
expression.We performed LC-MS/MS-based proteomic profiling
of quadriceps muscle from mice bearing the Colon-26 (C26)
adenocarcinoma and from mice administered Folfiri for 5 weeks
(Bonetto et al., 2012; Barreto et al., 2016). We then employed
a software-based analysis to identify upstream regulators and
causal networks associated with known diseases and functions.
Together, this study represents one of the first attempts to
perform a proteomic-based investigative approach in the skeletal
muscle of mice that are affected with cachexia with potential
translational implications for tumor-derived cachexia, as well as
muscle depletion due to chemotherapy.
MATERIALS AND METHODS
Animals
All experiments were conducted with the approval of the
Institutional Animal Care and Use Committee at Indiana
University School of Medicine and were in compliance with
the National Institutes of Health Guidelines for Use and care
of Laboratory Animals. In order to investigate the effect of
chemotherapy on muscle mass, 8-week old CD2F1 male mice
(n = 8; Harlan, Indianapolis, IN) were administered Folfiri, a
combination of 5-fluorouracil (50mg/kg), leucovorin (90mg/kg)
and CPT-11 (24mg/kg), intraperitoneally (i.p.), twice a week
for five consecutive weeks (Barreto et al., 2016). Based on
previous findings, the amounts of drugs that were delivered to
the experimental animals were not exceeding clinically relevant
concentrations (Barreto et al., 2016). Control mice received an
equal volume of vehicle. All drugs were purchased from Sigma
Aldrich (St. Louis, MO). For the cancer cachexia model, Colon26
cells were cultured in DMEM medium supplied with 10% fetal
bovine serum and 1% penicillin/streptomycin and maintained in
a 5% CO2, 37
◦C humidified incubator. Cells were passaged when
sub-confluent, and 1 × 106 cells were injected subcutaneously
in 8-week old CD2F1 male mice (n = 8). Non-tumor bearing
normal mice were used as controls. Mice were weighed daily
then euthanized under light isoflurane anesthesia. Tissues were
collected and weighed, then snap frozen in liquid nitrogen and
stored at−80◦C for further studies.
Sample Preparation
DL-Dithiothreitol (DTT), urea, triethylphosphine, iodoethanol,
and ammonium bicarbonate (NH4HCO3) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). LC-MS grade 0.1% formic
acid in acetonitrile (ACN) and 0.1% formic acid in water
(H2O) were purchased from Burdick and Jackson (Muskegon,
MI, USA). Modified sequencing grade porcine trypsin was
obtained from Princeton Separations (Freehold, NJ, USA). To
70mg of each of the liquid N2-pulverized quadriceps muscle
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samples, 400µL of 8 M urea/10mMDTT was added. Each tissue
sample was treated by light sonication and mixed for 1 h at
room temperature, followed by centrifugation at 13,000 rpm for
10min. The protein concentration was measured by Bradford
assay (Bradford, 1976). 20µL was removed and 20µL of 100mM
ammonium carbonate, pH 10.8, was added to the samples.
40µL of reduction/alkylation cocktail (97.5% acetonitrile, 2%
iodoethanol, and 0.5% triethylphosphine) was added to each
sample, and samples were incubated in a 37◦C incubator for 1.5 h.
The samples were speed vacuumed to dryness overnight, and the
dry pellets were resuspended in 50µL ammonium bicarbonate.
2.5µg trypsin in 100µL ammonium bicarbonate was added to
each sample, and they were incubated at 37◦C for 4 h. 2.5 µg
trypsin in 50 µL ammonium bicarbonate was then added to each
sample, and they were incubated at 37◦C overnight.
LC-MS/MS
The digested samples were analyzed using a Thermo Scientific
Orbitrap Velos Pro mass spectrometer coupled with a Surveyor
autosampler and MS HPLC system (Thermo Scientific). Tryptic
peptides were injected onto a C18 reversed phase column
(TSKgel ODS-100V, 3 µm, 1.0 × 150 mm) at a flow rate of
50µL/min. The mobile phases A and B were LC-MS grade
H2O with 0.1% formic acid and ACN with 0.1% formic acid,
respectively. The gradient elution profile was as follows: 5% B for
5min, 10–35% B for 150min, 35–80% B for 10min, 80% B for 10
min, and 5% B for 5 min. The data were collected in the “Data
dependent MS/MS” mode of FT-IT with the ESI interface using
normalized collision energy of 35% (CID). Dynamic exclusion
settings were set to repeat count 1, repeat duration 30 s, exclusion
duration 120 s, and exclusion mass width 10 ppm (low) and
10 ppm (high).
Peptide/Protein Identification and
Quantification
The acquired data were searched against the UniProt protein
sequence database of MOUSE (released on 06/24/2015) using
X1 Tandem algorithms in the Trans-Proteomic Pipeline (TPP,
v. 4.6.3) (http://tools.proteomecenter.org/software.php). General
parameters were: parent monoisotopic mass error set as 10 ppm,
cleavage semi set as yes, missed cleavage sites set at 2, and
static modification set as + 44.026215 Da on Cysteine. The
searched peptides and proteins were validated by PeptideProphet
(Ma et al., 2012) and ProteinProphet (Nesvizhskii et al.,
2003) in the TPP. Only proteins and peptides with protein
probability ≥0.9000 and peptide probability ≥0.8000 were
reported. False discovery rate (FDR) was estimated by a
non-parametric concatenated randomized target-decoy database
search (Elias and Gygi, 2007). For this experiment and those TPP
settings, protein identification FDR was <0.2%. Protein quantity
was determined using an in-house label-free quantification
software package, IdentiQuantXL, developed to individually and
accurately align the retention time of each peptide and to apply
multiple filters for exclusion of unqualified peptides to enhance
label-free protein quantification. As previously described in detail
(Lai et al., 2011), peptide retention time determination using
clustering, extraction of peptide intensity using MASIC (Monroe
et al., 2008), peptide coefficient of variation calculation, and
peptides correlation were all conducted within the software
platform to “filter out” unqualified peptides. Using only qualified
peptides, protein intensity was calculated using the formula:
Protein Intensity = (intensity of peptide 1)/(peptide 1 sharing
times)+ (intensity of peptide n)/(peptide n sharing times). For a
peptide shared by different proteins, the intensity of this peptide
was divided by the number of times the peptide was shared.
Raw data were deposited in the PeptideAtlas database and are
available through identifier PASS00863 (http://www.peptideatlas.
org/PASS/PASS00863).
Western Blotting
Total protein extracts were obtained by homogenizing 100mg
quadriceps muscle tissue in RIPA buffer (150mM NaCl, 1.0%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 50mM Tris,
pH 8.0) completed with protease (Roche, Indianapolis, IN)
and phosphatase (Thermo Scientific, Rockford, IL) inhibitor
cocktails. Cell debris were removed by centrifugation (15min,
14000 g) and the supernatant collected and stored at −80◦C.
Protein concentration was determined using the BCA protein
assay method (Thermo Scientific, Rockford, IL). Protein extracts
(30 µg) were then electrophoresed in 4–15% gradient SDS
Criterion TGX precast gels (Bio-Rad, Hercules, CA). Gels were
transferred to nitrocellulose membranes (Bio-Rad, Hercules,
CA). Membranes were blocked with SEA BLOCK blocking
reagent (Thermo Scientific, Rockford, IL) at room temperature
for 1 h, followed by an overnight incubation with diluted
antibody in SEA BLOCK buffer containing 0.2% Tween-20 at
4◦C with gentle shaking. After washing with PBS containing
0.2% Tween-20 (PBST), the membrane was incubated at room
temperature for 1 h with either Anti-rabbit IgG (H+L) DyLight
800 or Anti-mouse IgG (H+L) DyLight 600 (Cell Signaling
Technologies, Danvers, MA). Blots were then visualized with
Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln,
NE). Optical density measurements were taken using the Gel-
Pro Analyzer software. Antibodies used were OPA-1 (#80471),
Mitofusin-2 (#9482), DRP-1 (#8570), Cytochrome C (#11940)
from Cell Signaling Technologies (Danvers, MA), PGC-1α
(#ab3242) from Abcam (Cambridge, MA) and α-Tubulin
(#12G10) from Developmental Studies Hybridoma Bank (Iowa
City, IA).
Statistics
Comparisons among tissue weights reported in Table 1 were
carried out using Student’s t-test. A value of p ≤ 0.05
was considered statistically significant. As for the LC-MS/MS
proteomic study, only the proteins identified with at least
two peptides and with −1.5 ≥ fold change (FC) ≥ +1.5
were included in the analysis. Comparative analysis between
the two datasets was carried over by means of Correlation
Engine (Illumina, San Diego, CA). Finally, statistically significant
and differentially expressed proteins (FDR < 5%) from both
datasets were imported into Ingenuity Pathway Analysis (IPA;
Qiagen, Valencia, CA) to identify significant pathways, upstream
regulators and causal networks associated with known diseases
and functions.
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TABLE 1 | Body and tissue weights in tumor-bearing mice and chemotherapy-treated animals.
Cancer Chemotherapy
Control (n = 8) C26 (n = 8) Vehicle (n = 8) Folfiri (n = 8)
IBW 25.35±1.61 26.60± 1.12 26.70± 1.70 24.6± 2.70
FBW 25.62±1.80 22.4± 2.63a 28.80± 1.70 24.6± 3.10bb
GSN 0.57±0.02 0.44± 0.03aaa 0.55± 0.04 0.49± 0.01bb
Quadriceps 0.74±0.05 0.56± 0.08aaa 0.77± 0.05 0.62± 0.02bbb
Heart 0.53±0.02 0.45± 0.06aa 0.57± 0.04 0.61± 0.02
Liver 4.52±0.23 4.65± 0.64 4.88± 0.52 4.95± 0.34
Spleen 0.28±0.03 1.09± 0.81aaa 0.27± 0.03 0.81± 0.12bbb
Fat 2.25±0.35 0.89± 0.45aaa 2.89± 0.54 1.08± 0.32bbb
Data are expressed as means± SD. Initial body weight (IBW) and Final body weight (FBW) are reported in grams (g). Gastrocnemius (GSN), quadriceps, liver, spleen and fat are reported
as weight/100mg IBW. Significance of the differences: ap < 0.05, aap < 0.01, aaap < 0.001 vs. Control; bbp < 0.01, bbbp < 0.001 vs. Vehicle.
RESULTS
Tumor Growth and Chemotherapy
Administration Promote the Occurrence of
Severe Cachexia
In order to limit the variability across the different animalmodels,
both tumor hosts and animals treated with chemotherapy were
sacrificed when muscle loss was comparable (about 15%) and
resembling a condition of severe cachexia, as previously shown
(Bonetto et al., 2011). In particular, CD2F1 male mice (n = 8)
were injected s.c. with C26 adenocarcinoma cells and weighed
daily. After 14 days from tumor injection, tumor hosts were
sacrificed when their final body weight reached about 87% of
the control animals (p < 0.01) (Table 1) (Bonetto et al., 2011).
In this setting, marked muscle wasting was observed, both at the
gastrocnemius and quadriceps level (−23 and −25% vs. control,
respectively; p < 0.001). A condition associated with cardiac
atrophy was also displayed and is associated with tumor growth
(−15% vs. control; p< 0.01). Similar to that previously described
in the same experimental model of cancer cachexia (Bonetto
et al., 2011, 2012), severe depletion of adipose tissue (−61% vs.
control; p< 0.001), as well as splenomegaly (+289% vs. control; p
< 0.001), were observed (Table 1). In separate set of experiments,
CD2F1 normal mice were administered Folfiri (twice/week)
for 5 weeks, and body weight was monitored daily (Barreto
et al., 2016). At the time of sacrifice, the chemotherapy-treated
mice showed significant loss of body weight (−15%, p < 0.01),
consistent with depletion of gastrocnemius (−11%, p < 0.01),
quadriceps (−20%, p < 0.001), and fat (−63%, p < 0.001) mass.
Interestingly, the heart mass was not affected by chemotherapy
administration. Similar to the tumor-bearing animals, a dramatic
increase in spleen size (+200% vs. vehicle, p < 0.001) was also
observed (Table 1).
C26 Tumor and Folfiri Influence the
Skeletal Muscle Proteome
In order to elucidate the mechanisms responsible for muscle
wasting in cancer-associated cachexia and chemotherapy-
induced cachexia, we investigated the muscle proteome in C26
hosts and in mice treated with Folfiri. By taking advantage of a
LC-MS/MS quantitative approach, we detected 422 proteins in
the muscle of animals carrying the C26 tumor and 511 proteins
in the muscle of mice exposed to chemotherapy (Tables S1–S3).
Of note, 269 proteins, among the ones identified with at least
two peptides and with −1.5 ≥ fold change (FC) ≥ +1.5,
were differently expressed in the C26 hosts, while 386 were
significantly (p < 0.05) modulated in the muscle of animals
treated with Folfiri (Table S4).
In particular, among the 269 proteins modulated in the cancer
setting, 235 were down-regulated, while 34 were up-regulated
(Figure 1A, Table S4). Analogously, following chemotherapy
administration, a large majority of proteins (345) were down-
regulated, while only a small subset of proteins (41) was up-
regulated or expressed exclusively in the muscle of animals
receiving Folfiri (Figure 1A, Table S4). Comparative analysis
performed by means of Illumina Correlation Engine identified
240 proteins that were modulated in both experimental
conditions (p = 3.3E-244), with a significant positive correlation
(218 proteins; p < 1.0E-323) for the proteins that were down-
regulated in both experimental models (Figure 1B). Quite
interestingly, members of metabolic pathways (39.1% in Folfiri,
44.5% in C26) and structural proteins (24.4% in Folfiri, 21.9% in
C26) were the most represented in both subsets (Figure 1C, left
and middle panels). A similar situation was also observed among
the 240 proteins modulated in common, with metabolic and
structural proteins representing the large majority and totaling
about 68% (Figure 1C, right).
Muscle Mitochondrial Dysfunctions Are the
Main Event Associated with Tumor Growth
or Chemotherapy Treatment
The IPA-based analysis performed on the proteins detected
in both datasets identified a series of pathways that were
similarly affected by both cancer and chemotherapy (Figure 2).
In particular, the most represented among the Top-20 pathways
influenced by either tumor growth or chemotherapy treatment
were associated with mitochondrial dysfunctions, but also
alterations of oxidative phosphorylation, TCA cycle, epithelial
and tight junction signaling, glycolysis, fatty acid β-oxidation and
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FIGURE 1 | Cancer and chemotherapy promote the down-regulation of 235 and 345 muscle proteins, respectively. (A) Pie charts showing the number of
proteins that are down-regulated (green) or up-regulated (red) following tumor growth (C26, left) or chemotherapy (Folfiri, right). (B) Comparative analysis between C26
and Folfiri biosets (Bs 1 and Bs 2, respectively). The Venn diagram (left) shows the number of proteins that are modulated in common or in the presence of either C26
or Folfiri. The overlap p-value, indicating the statistically significant overlap between the two datasets, is also reported. Analogously, the significance of the overlap
between different protein subsets within the group of proteins modulated in both subsets is also presented (right). (C) The proteins detected in the C26 (left) and Folfiri
(middle) datasets, or modulated in common (right) were classified based on their function and/or pathway and distributed as shown in the pie charts. The percentage
is expressed over the total number in proteins in each dataset.
protein kinase A (Figures 2, 3A; Table S4). Here we show that
proteins taking part to the β-oxidation were markedly reduced
in the C26-bearing animals, while regulators of the synthesis of
fatty acids, such as FAS, TKT and PDK4, were significantly up-
regulated (Figures 3A,C; Table S4). Similarly, members of the
respiratory chain, such as NDUS6, NDU5, and CISD1, were
not detected in the muscle of tumor hosts, suggesting that the
energetic metabolism was severely compromised (Figures 3A,C;
Table S4). Interestingly, all proteins modulated in the Folfiri
dataset were drastically down-regulated with few exceptions,
namely several enzymes involved in the metabolism of lipids
(PLIN1, HSD17B10, FASN, and ACOT2) or amino acids, such
as leucine and valine (IVD, HIBCH, ALDH6A1), the GMP
reductase 1 (GMPR) involved in the synthesis and conversion
of nucleotides, two regulators of the Krebs cycle (MCP2 and
PCCB), and two members of the mitochondrial respiratory chain
(NDUFB8 and UQCR10) (Figures 3A,C). In line with these and
previous observations (Pin et al., 2015; Barreto et al., 2016),
alterations of muscle mitochondrial homeostasis, as suggested
by the levels of markers of mitochondrial fusion (OPA-1,
mitofusin-2), fission (DRP-1) and biogenesis (Cytochrome-C,
PGC-1α), were displayed in the muscle of both C26 hosts and
animals exposed to chemotherapy (Figure 4).
In line with previous observations (Costelli and Baccino, 2003;
Fearon et al., 2012), we also show that the levels of PSMA6 and
UBA1, major proteasomal components, were increased in the
muscle of Folfiri-treated animals. Similarly, UBA1 and UB2L3,
enzymes associated with the proteasome system, were also up-
regulated in the muscle of C26 hosts (Table S4).
Of note, epithelial and tight junction signaling, as well
as actin cytoskeleton and calcium signaling, were modulated
following either C26 growth or Folfiri treatment (Figures 2,
3B,C; Table S4). In particular, 15 calcium-binding proteins
were markedly down-regulated by Folfiri administration, thus
suggesting a deregulation of these pathways (Figures 3B,C;
Table S4). Interestingly, structural proteins, such as KERA and
LAMA2, were up-regulated in the muscle of both Folfiri-treated
animals and tumor-bearing mice (Figures 3B,C; Table S4),
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FIGURE 2 | Pathway analysis of muscle proteomic profiling in cancer or chemotherapy-induced cachexia. By utilizing the IPA software, the C26 and Folfiri
datasets were subjected to pathway analysis. The pathways were ranked based on their overlap p-value (bars). Top-20 pathways are reported in the diagram, along
with the number of proteins modulated within each pathway (triangles).
unlike other proteins, such as MYOZ2, overexpressed in
the muscle of C26 hosts and, conversely, down-regulated
in the muscle of chemotherapy-treated animals (Table S4).
Interestingly, proteins of the 14-3-3 family were down-regulated
both in tumor hosts and Folfiri-treated animals (Table S4).
Furthermore, in line with our previous findings (Bonetto et al.,
2011), the expression of the majority of the identified positive
acute phase response (APR) proteins (CO3, FIBA, FIBB, FIBG,
and HPT) was more elevated in the muscle of C26 hosts with
respect to the controls, while all negative APRs (TTHY, TRFE
and ALBU) were down-regulated (Figure 3C; Table S4). Also,
in the presence of chemotherapy, the expression of a number
of proteins associated with inflammatory pathways was affected,
although the large majority of these mediators were generally
down-regulated (Figure 3C; Table S4).
Similar Mechanisms Are Likely
Responsible for Muscle Wasting in Both
C26- and Folfiri-Associated Cachexia
The “Upstream Regulator Analysis” predicted which
transcriptional regulators are involved upstream of the changes
observed and whether they are likely activated (z-score > 2)
or inhibited (z-score < −2). In particular, among the Top-20
upstream regulators expected to be activated in both datasets,
the histone lysine demethylase KDM5A, the mTORC2 subunit
RICTOR, the mitogenic-activated protein kinase isoform 4
(MAP4K4), and the contraction regulator Smoothelin-like 1
(SMTNL1) showed the highest p-value, providing evidence
of a statistically significant overlap between our data and the
pathways generally associated with these transcription factors
(Figures 5A–C). Conversely, among the Top-20 upstream
regulators characterized by a z-score < −2 (i.e., likely inhibited)
in the skeletal muscle of mice either carrying the C26 tumor or
treated with Folfiri, the insulin receptor (INSR), the Peroxisome
Proliferator-Activated Receptor Gamma Co-activator 1 Alpha
(PPARGC1A, also known as PGC1α) and the tumor suppressor
gene RB1 were the highest ranked, whereas the insulin-like
growth factor-1 receptor (IGF1R), the regulators of muscle
differentiation MYOD1 andMEF2C, as well as other members of
the Peroxisome Proliferator-Activated Receptor Gamma family
were also identified with lower p-values (Figures 5B–D). Of note,
no major difference between the two datasets were reported, thus
further supporting the idea that similar mechanisms contribute
to muscle wasting in both experimental conditions.
Muscle Disorders and Alterations of
Energy Production and Nucleotide
Metabolism Are Associated with Cachexia
Due to Cancer or Chemotherapy
The “Disease and Function Analysis” anticipated which
alterations were likely associated with the protein changes
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FIGURE 3 | Major pathways affected in cancer- and drug-induced cachexia. (A) Proteins belonging to any metabolic pathway are indicated and classified as
shown in color legend (right). Proteins up-regulated in almost one comparison (C26 vs. control or Folfiri vs. vehicle) are shown in red. All other proteins reported are
(Continued)
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FIGURE 3 | Continued
down-regulated. (B) Structural proteins, calcium- and proteasome-associated proteins affected by either cancer or chemotherapy. (C) Number of proteins taking part
to any of the major pathways affected in cancer- and chemotherapy-induced cachexia. Up-regulated proteins are reported in red, down-regulated proteins are shown
in green.
FIGURE 4 | The expression of markers of mitochondrial fusion, fission and biogenesis is affected by tumor and drug-induced cachexia. (A)
Representative western blotting for OPA-1, Mitofusin-2, DRP-1, Cytochrome-C (Cyt-C), and PGC-1α in the muscle of C26 hosts or mice exposed to Folfiri. (B,C)
Quantification of the bands (n = 4). Significance of the differences: *p < 0.05, **p < 0.01, ***p < 0.001 vs. Control or Vehicle.
reported in the muscle of tumor hosts or in mice exposed
to chemotherapy. Interestingly, in both datasets, movement
disorders, damage or death of muscle cells and muscle
weakness/fatigue were activated (z-score > 2), (Figures 6A–C).
Further, cardiac dysfunctions seemed to be associated
exclusively with tumor growth (Figure 6A), consistent with
the decrease in heart mass shown in Table 1. Similarly, the
evidence of drug-related neurotoxicity was reported only
in the Folfiri dataset (Figure 6B). Conversely, inhibition of
nucleotide metabolism and synthesis of ATP, as well as reduced
muscle function and modification of ROS, were predicted
in both experimental conditions (Figures 6B–D), while
alterations of fatty acid metabolism and lipid oxidation
were only associated with the chemotherapy treatment
(Figure 6D).
DISCUSSION
Cachexia is a devastating syndrome associated with many disease
states, such as cancer, congestive heart failure, diabetes, kidney
failure, and HIV/AIDS (Bonetto et al., 2012; Fearon et al.,
2012; Dutt et al., 2015). Cancer cachexia is characterized by
systemic inflammation, negative protein and energy balance,
and an involuntary loss of lean body mass, with or without
wasting of adipose tissue (Aoyagi et al., 2015). Muscle weakness
has been postulated to occur due to a combination of muscle
breakdown, dysfunction, and a decrease in the ability to repair
(Isaac et al., 2016). Effective therapies are presently limited,
whereas the removal of the primary tumor remains the only
definitive treatment strategy. The idea that anticancer treatments
may also result in muscle atrophy is currently being debated.
Along this line, we recently reported that chemotherapy regimens
utilized for the therapy of colorectal cancer, such as Folfox
and Folfiri, drive alterations consistent with muscle wasting
and muscle weakness (Barreto et al., 2016). Despite this, the
mechanisms responsible for muscle loss in the presence of
anticancer treatments are not completely known. Furthermore,
it is not clear whether similar mechanisms are activated in
the presence of either cancer or chemotherapy, thus leading to
muscle wasting.
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FIGURE 5 | Upstream regulators in C26- and Folfiri-induced cachexia. The IPA-mediated analysis identified several upstream regulators ranked based on their
overlap p-value, whose activation (z-score > 2) or inhibition (z-score < −2) is associated with the phenotype observed. Top panel: Top-20 upstream regulators
activated (A) or inhibited (B) in C26 cachexia. Bottom panel: Top-20 upstream regulators activated (C) or inhibited (D) in Folfiri-associated cachexia.
It has been suggested that anorexia, i.e., the reduced or loss of
the desire to eat, may represent one of themajor causes associated
with body and muscle weight loss in oncologic patients (Molfino
et al., 2010). Despite the fact that anorexia has been shown to
play a role in the development of cachexia in several experimental
models, in the present research work we assessed the proteomic
profiling in animals only based on the amount of muscle
wasting. Moreover, based on available studies, pair-feeding was
not performed, particularly because previous results have shown
that muscle protein waste is mainly associated with acceleration
of protein breakdown rates, regardless of food intake, whereas in
pair-fed animals the decrease of skeletal muscle protein content
is mainly due to impaired protein synthesis (Tessitore et al.,
1993). Therefore, reduced food intake andmetabolic competition
by the tumor do not seem to justify the hypercatabolic state
in the tumor hosts. This view also is shared by the ground-
breaking report from Lecker et al. (2004). Similarly, Garcia et al.
(2013) showed that cisplatin administration normally affects food
intake. However, pair feeding experiments carried out in the same
report showed that chronic administration of cisplatin did not
induce anorexia and that animals receiving chemotherapy were
showing exacerbated body weight loss, regardless of their food
intake (Garcia et al., 2013). More recently, in another model we
showed that chronic administration of Folfiri to normal animals
does not cause anorexia and is only responsible for acute toxicity
associated with sudden and temporary drops in food intake,
while, on the contrary, the cumulative food intake does not differ
from the vehicle-treated animals (Barreto et al., 2016).
In the present experimental work the proteomic analysis
performed in skeletal muscle revealed a similar impairment
of several metabolic pathways and muscle structures, also
consistent with previously published observations (Fontes-
Oliveira et al., 2013; Pin et al., 2015; Barreto et al., 2016).
Along this line, the large majority of all metabolic enzymes,
particularly those associated with the maintenance of the
aerobic catabolism (i.e., Krebs cycle and respiratory chain), were
drastically down-regulated in both datasets, further supporting
the idea that muscle wasting due to chemotherapy administration
can be defined as real cachexia. Indeed, oxidative pathways
and mitochondrial abnormalities with consequent decreased
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FIGURE 6 | Diseases and functions associated with C26- and Folfiri-induced cachexia. The IPA software identified diseases and functions, ranked based on
their overlap p-value, expected to be activated (z-score > 2) or inhibited (z-score < −2) in the C26 and Folfiri datasets. Top panel: diseases and functions activated
(A) or inhibited (B) in C26 cachexia. Bottom panel: diseases and functions activated (C) or inhibited (D) in Folfiri-associated cachexia. Only the Top-20 diseases and
functions are reported in the diagram, along with the number of correlated proteins (triangles).
production of ATP are already well documented features of
cachexia and suggest that changes in these pathways might
also contribute to muscle weakness, as frequently observed in
association with chemotherapy (Fontes-Oliveira et al., 2013;
Argilés et al., 2015; Barreto et al., 2016; Carson et al.,
2016). In addition, mitochondrial alterations associated with
decreased expression of markers of mitochondrial fusion and
fission that are normally involved in the maintenance of the
integrity and plasticity of the mitochondrial network (Pernas
and Scorrano, 2016) were also reported in the muscle of
both C26 bearers and mice treated with chemotherapy. This
is also consistent with previous reports from our group
and others that suggest that cachexia is generally associated
with severe alterations of the muscle mitochondria, which
may contribute to the occurrence of muscle atrophy, muscle
weakness, as well as the transition to more glycolytic muscle
fibers (Pin et al., 2015; Barreto et al., 2016). Interestingly,
mitochondrial dysfunctions and increased oxidative stress
have been shown to play a role in causing disruptions of
the neuromuscular junctions, thus possibly explaining the
occurrence of muscle weakness and fatigue following cancer
development or chemotherapy treatment (Ibebunjo et al., 2013).
This is also consistent with our data showing abnormal junction
signaling in the muscle of tumor hosts and animals treated with
Folfiri.
Notably, our data also show that a few significant differences
exist between the two experimental conditions. In particular,
all the enzymes of the aerobic metabolism contributing to the
Krebs cycle or the respiratory chain aremarkedly down-regulated
in the muscle of tumor hosts, while the same response is
not observed following chemotherapy administration, where a
considerable number of proteins appear up-regulated. Similarly,
pathways associated with the lipidic metabolism were enhanced
by the presence of the C26 adenocarcinoma and substantially
inhibited following Folfiri administration. In particular, here
we showed that tumor growth is associated with decreased
activation of the β-oxidation, generally associated with the
breakdown of lipids and fatty acids. Interestingly, the synthesis
of FAS and TKT, normally associated with the synthesis of fatty
acids, were significantly up-regulated. This apparent discrepancy
with the phenotype observed in tumor hosts, characterized
by severe depletion of fat tissues, may actually result from a
survival mechanism that attempts to restore the fat stores, which
are essential in a conditions associated with reduced energy
metabolism. To further support this point, we also showed that
members of the respiratory chain were not detectable in the
muscle of tumor hosts, suggesting that the energetic metabolism
was impaired.
Our analysis also provides evidence of a concerted down-
regulation of structural proteins and calcium-related proteins
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in the muscle of cachectic mice. In particular, alterations
of calcium homeostasis have been reported in clinical and
experimental cachexia and other inflammation-driven muscle
diseases (Isaac et al., 2016), analogously to the impairment of
sarcoplasmic structure (Fontes-Oliveira et al., 2013). A large
number of calcium-related proteins and almost all structural
proteins that were detected were also shown to be down-
regulated in tumor-bearing mice, coherently with the loss of
skeletal muscle mass and the occurrence of muscle weakness
(Bonetto et al., 2009; Waning et al., 2015). Furthermore, proteins
of the 14-3-3 family were also shown to be decreased both
in tumor hosts and Folfiri-treated animals. Interestingly, these
proteins were recently identified as novel myokines required for
maintaining myosin content in skeletal muscle (McLean et al.,
2015).
A number of other factors in cancer patients are known to
increase the catabolic response, leading to unsustainable levels
of fat and muscle mobilization and levels of muscle depletion
that cause significant morbidity and mortality (Aoyagi et al.,
2015). The up-regulation of proteasomal components observed
in association with the occurrence of cachexia is consistent with
the well-known activation of skeletal muscle degradative systems,
such as the ATP-ubiquitin-dependent one (Bossola et al., 2001;
Onesti and Guttridge, 2014). This has also been suggested by the
overexpression of muscle-specific ubiquitin ligases, as previously
reported in conditions associated with cancer cachexia (Lecker
et al., 2004). Conversely, we recently showed that mechanisms
other than the ones associated with the activation of proteasome-
dependent muscle catabolism are responsible for muscle wasting
after Folfiri treatment (Barreto et al., 2016). Regardless, here
we show that the levels of major proteasomal components were
increased in the muscle of Folfiri-treated animals. Similarly,
enzymes associated with the proteasome system were also up-
regulated in the muscle of C26 hosts. The discrepancy with
our previous data may also suggest that the proteasome-
dependent systems might have been involved in promoting
chemotherapy-dependentmuscle depletion at earlier time points,
consistent with findings associated with cachexia (Lecker et al.,
2004).
In line with previous reports, a robust skeletal muscle APRs
transcriptomic response in association with the activation of
muscle catabolism was confirmed in the muscle of C26-bearing
mice (Bonetto et al., 2011). Also in this case, the response
associated with tumor growth was more coordinated than
that following administration of Folfiri. Inflammation and high
APR levels are considered a hallmark of cancer cachexia, and
an integrated physiological response of substrate mobilization
driven by inflammation was proposed as mainly responsible
for the development of cachexia (Aoyagi et al., 2015). Despite
this, the specific mechanisms by which these cytokines produce
skeletal muscle dysfunction remain partially undefined (Isaac
et al., 2016). It has been hypothesized that hepatic synthesis
of positive acute phase response proteins using amino acids
liberated from skeletal muscle proteins is a major driver of
skeletal muscle proteolysis (Bonetto et al., 2011). In particular,
the levels of fibrinogen expressed in liver vs. muscle in this
experimental model suggest thatmusclemight be a greater source
of APR proteins than liver (Bonetto et al., 2011).
In the present work, we show that most of the APR proteins
are evenly increased in the muscle of mice carrying a tumor or
chronically administered chemotherapy, thus supporting the idea
that amino acids freed from skeletal muscle structural proteins
through proteolysis would be re-synthesized into these secreted
proteins and exported from the cell, possibly contributing to
muscle wasting (Bonetto et al., 2011). Altogether, this might
suggest that the mechanisms responsible for muscle depletion
in the presence of a tumor are also playing a role in promoting
muscle wasting upon administration of chemotherapy. In
particular, and coherent with our previous findings (Bonetto
et al., 2011), a large number of proteins associated with
inflammatory pathways was affected both in the presence of
cancer or chemotherapy, although in the latter the large majority
of these mediators were generally down-regulated.
In conclusion, in the present study we aimed at investigating
whether in vivo chemotherapy administration could drive the
development of cachexia similarly to cancer alone. In particular,
in order to unravel the direct modulatory effects of either
cancer or chemotherapy on muscle proteome we analyzed the
proteomic profiling in the skeletal muscle of C26 tumor hosts
or animals exposed to Folfiri. Our study design did not take
into consideration the complexity of the interactions between
tumor- and chemotherapy-driven mediators, thus apparently
representing a limitation. Despite recognizing the importance
of future investigations particularly designed to fill this gap
of information, we believe this approach was required to
assess the effects that are exclusively dependent on the use of
anticancer drugs and to definitively include the derangements
associated with chemotherapy treatment among the conditions
characterized by the occurrence of a cachectic phenotype. Along
this line, the data in the present study showed remarkable
similarities to the proteomic signatures of cachectic muscles
from mice carrying tumors or exposed to chemotherapy, thus
further validating the idea that anticancer therapies play a
substantial role in causing muscle wasting and muscle weakness,
similar to cancer. Analogously, the expected disease pattern
associated with the described phenotypes was similar in both
experimental conditions, which is consistent with the state
of activation of the putative upstream regulators. Of note,
signs of neurotoxicity were expected exclusively after Folfiri
administration, which is consistent with previous findings that
report chemotherapy-related neurotoxicity and muscle weakness
(Cordier et al., 2011; Barreto et al., 2016; Taillibert et al., 2016).
Ultimately, we showed that dysfunctions of the mitochondrial
metabolism represent the main consequence associated with
the development of cachexia, thereby corroborating the idea
that strategies aimed at protecting the muscle mitochondrial
pool may, at the same time, contribute to preserve muscle
mass and muscle function in the occurrence of cancer or in
association with chemotherapy. Based on our results, future
studies will warrant the combination of strategies aimed to
both counteract tumor growth and reduce the side effects of
chemotherapy.
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